polymerase chain reaction; hematopoietic stem cell transplantation
The incidence of adenoviral (AdV) infection in hematopoietic stem cell transplantation (SCT) recipients has been reported to be 9-31.3%, [1] [2] [3] [4] while the mortality rate of AdV disease has been estimated to be as high as 1-60%. 2, 4, 5 The outcome in pediatric patients 1 is even worse, with an estimated mortality rate up to 21-31.3%. 1, 3, 4 In children, AdV-induced hemorrhagic cystitis, which is mostly caused by the virus with serotype 11, 34, and 35 in the subgroup B, often occurs during the early post-SCT period 1, 6, 7 and occasionally leads to systemic dissemination associated with poor prognosis. [8] [9] [10] Early diagnosis of AdV infection during the pre-and post-SCT periods is essential to prevent such dismal outcomes. 9, 11, 12 However, confirmation of AdV disease associated with hemorrhagic cystitis is not easy. Symptoms similar to those associated with AdV (fever, urodynia, hematuria, etc.) may also occur in SCT recipients due to acute GVHD or to adverse effects of conditioning regimens.
At least three laboratory procedures have been available for the diagnosis of AdV infection: viral isolation by the latex agglutination reaction method, and molecular detection by polymerase chain reaction (PCR) 13 or Southern blot analysis. 14 The real-time PCR method has recently been introduced into clinical virology for quantitative detection of viral copy numbers. In this study, we evaluated this procedure for its utility in the diagnosis of AdV infection in the pre-and post-SCT periods. Although the study was retrospective, our data clearly indicate that prospective, quantitative detection of the AdV genome in serum and urine can be useful for predicting the development of AdV disease in SCT recipients.
Materials and methods

Patients and specimens
Seven patients with hematological malignancies who received SCT between 1999 and 2001 were included in this retrospective study. Characteristics of these patients are summarized in Table 1 . SCT in these four male and three female patients with a median age of 13 years (range: 8-16) was allogeneic-related in two patients, allogeneic-unrelated (including one cord blood) transplantation in four patients, and auto peripheral blood SCT in one patient. The conditioning regimen was a combination of TBI, BU, and L-PAM in four patients, a combination of TBI and CY in two patients, and a combination of BU, CY, and L-PAM in the remaining patient. To prevent acute GVHD following allogeneic SCT, all patients received a short-course of methotrexate and cyclosporine A with or without methyl-prednisolone. Informed consent of the study was obtained from the institution and the patients' guardians.
Diagnosis of AdV disease
The presence of clinical signs and symptoms of hemorrhagic cystitis, such as fever, urodynia, and hematuria associated with the positive AdV isolation and/or frequent detection of the AdV genome by real-time quantitative PCR in urine/sera resulted in the diagnosis of AdV disease. Based on this criterion, three of the seven SCT recipients developed AdV disease. One of the three (Case 1) was previously reported. 15 
Specimens
At various time points during the pre-SCT period and up to 7 weeks post-SCT, 66 sera and 51 urine specimens were obtained from the seven SCT recipients. For control specimens, we collected 75 urine specimens from 3-yearold infants at a well-infant clinic, eight sera specimens from pediatric (o3 year old) patients without apparent infectious disease, and seven cord blood specimens. All specimens were stored at À801C until assay. Standard AdV strains with known serotypes were obtained from the Virology Department at the Kyoto City Institute of Health and Environmental Sciences.
DNA extraction
In all, 500 ml of serum was passed through a 0.45 mm filter to remove cell contamination and then subjected to a QIAamp blood kit and eluted in 50-100 ml distilled water (Qiagen, Hilden, Germany) following the manufacturer's protocol. For urine analysis, 2 ml of urine were applied to the microconcentrator and centrifuged at 3000 rpm for 30 min to obtain a final volume of 140 ml before analyzing with the QIAamp kit. All DNA specimens prepared were qualitatively evaluated by amplifying the b-actin gene by PCR.
Real-time quantitative PCR
The primers and probe for this assay were set up to the hexon region (nucleotide position 20977-21064), which is recognized as the stable region for all AdV serotypes. The upstream and downstream sequences, 5 0 -CAGGTA-GACTGCCTCGATGATG-3 0 and 5 0 -GCCCACCCTGC-TTTATCTTCTC-3 0 , respectively, were synthesized by TaKaRa Shuzo (TaKaRa, Otsu, Japan). A fluorogenic probe sequence of 5 0 -(FAM) TGCACTCTGACCACGTC- GAAAACTTC (TAMRA)-3 0 was located between the PCR primers, which was custom synthesized by Applied Biosystems (Foster City, CA, USA). Sequence data for the AdV genome was obtained from the GeneBank Sequence Database (accession number NC001405). Fluorogenic PCR reactions were carried out in a reaction volume of 50 ml containing 5-10 ml of DNA sample and 40 ml of the PCR mixture containing 10 mM Tris (pH 8.3), 50 mM KCL, 10 mM EDTA, 5 mM MgCl 2 , 100 mM dATP, dCTP, dGTP, and dTTP, 0.25 mM of each primer, 0.1 mM fluorogenic probe, and 1.25 U of ampliTaq Gold (Applied Biosystems; Branchburg, NJ, USA). Each specimen was analyzed in triplicate. Following activation of the ampliTaq Gold for 10 min at 951C, 40-45 cycles of PCR for 15 s at 951C and for 1 min at 621C were carried out using a model Gene Amp 5700 Sequence Detector System (Applied Biosystems). Real-time fluorescence measurements were taken, and a threshold cycle (Ct) value for each sample was calculated by determining the point at which the fluorescence exceeded a threshold limit (10 times the standard deviation of the baseline). A plasmid containing the hexon gene (nucleotide position; 20977-21064) was constructed from a pCR2.1 vector (Invitrogen, Carlsbad, CA, USA) as a positive control and was termed pCR2.1-hexon. Ct values from clinical specimens were plotted on a standard curve, and the copy number was calculated automatically by a software package for data analysis (Sequence Detector version 1.3, Applied Biosystems). The detection limit in our assay system was 1 copy/reaction tube, which was comparable to the cutoff of 50 copies/ml of serum and 50 copies/mg creatinine (Cre) in urine.
Specificity and sensitivity of the assay system
In the preliminary assay, we confirmed that these primers and probe were highly sensitive for the detection of the AdV with serotype 3, 7, 11, and 35, but not with serotype 1, 2, 5, 6, 19, and 40/41. We were not able to test the AdV with other serotypes. Previously, we employed the cutoff for genome detection in serum at 50 copies/ml; 15 however, since the values of control serum specimens were distributed between fewer than 50-200 copies/ml, we set it in this study at 200 copies/ml. The cutoff in urine was the same 50 copies/mg Cre, as previously reported. 15 
Statistical analysis
The software package Statview J 4.02 (Abacus Concepts Inc., Berkeley, CA, USA) was used for data analysis. The Mann-Whitney U test was used for comparison of AdV genome copy numbers in serum and urine between the SCT recipients and controls.
Results
Comparison of AdV genome copy numbers between SCT recipients and controls
The distribution of AdV genome copy numbers in serum and urine is comparatively illustrated in Figure 1 . In sera, 59 specimens were obtained at various time points (from pre-SCT to the seventh week post-SCT) from the seven SCT recipients and one specimen from each of the 15 control subjects. The AdV genome was detected in 37/59 of the sera from the SCT recipients and in 1/15 from the controls (Po0.05). Levels of higher than 10 5 copies/ml were measured in 16/59 of the sera from the SCT recipients, especially in the patients with AdV disease, and in 0/15 from the controls (Po0.05) (Figure 1a) . A total of 48 urine specimens from the seven SCT recipients and 75 urine specimens from the control subjects were analyzed (Figure 1b) . The AdV genome was detected in 18/48 of the urine specimens from the SCT recipients and in 3/75 specimens from the controls (Po0.05). Levels above 10 3 copies/mg Cre were detected in only three patients with AdV disease.
AdV genome detection in serum and urine specimens in preand post-SCT periods
The AdV genome in pre-SCT urine specimens obtained from three recipients was negative, while that in pre-SCT serum specimens in two of five recipients tested was positive, and these two recipients later developed AdV Figure 1 Comparison of AdV genome copy numbers in serum (a) and urine (b). The detection limits of the AdV genome were 2 Â 10 2 copies/ml in serum and 50 copies/mg Cre in urine, respectively. (Symbols: B ¼ AdV genome copy numbers in serum, and E ¼ AdV genome copy numbers in urine.) Statistical analysis was performed by the Mann-Whitney U test.
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disease. During the post-SCT period, the AdV genome was detected in urine 1-2 weeks post-SCT in three recipients who subsequently developed AdV disease. During the 4-6 weeks post-SCT, five recipients showed serum levels of 410 3 copies/ml, but in two recipients who did not have AdV disease, detection of high copy numbers were transient. The highest levels of greater than 10 5 copies/ml in sera were noted in the three patients with AdV disease ( Table 2) .
Sequential detection of AdV genome copy numbers in three patients with AdV disease
As summarized in Table 1 and illustrated in Figure 2 , three patients developed an AdV disease. Case 1 (Figure 2a) : We reported previously that the AdV genome was not detected in one serum specimen at pre-SCT period; 15 however, data in Case 3 prompted us to check one more specimen stored at day À14, which was found to have high AdV genome copy numbers. The AdV genome level reduced during conditioning, and it was detected again on day þ 14. The patient had hematuria with fever on day þ 20, when AdV with serotype 35 was isolated from the patient's urine specimen. Hematuria and fever persisted, but the high serum levels of 2.4 Â 10 9 copies/ml during the period 4-6 weeks post-SCT gradually decreased in response to the treatment with Rivabirin and Vidarabin. The patient currently suffers from cardiac and renal insufficiency. Case 2 ( Figure 2b ): The AdV genome was first detected in the urine on day þ 12 post-SCT, in association with fever, urodynia, and hematuria. AdV with serotype 11 was isolated from urine on day þ 20. The urinary AdV genome reached 7.3 Â 10 6 copies/mg Cre, and anuria ensued on day þ 35. The patient's serum AdV genome was not available at pre-SCT period, but it gradually increased to the peak value of 1.7 Â 10 8 copies/ml on day þ 48. The patient died of severe AdV disease. Case 3 (Figure 2c ): The AdV genome was already detectable at 4.0 Â 10 3 copies/ml in the pre-SCT period, and the patient had fever and hematuria early on day þ 10. The AdV genome copy numbers in urine were as high as 10 6 copies/mg Cre at this time. The disease was progressive and fatal, with serum AdV genome levels at 1.2 Â 10 6 copies/ml on day þ 30, although no virus was isolated from the patient's urine specimens. Postmortem multiplex PCR examination and restriction fragment length polymorphism (RFLP) of AdV in urine revealed that the patient had the AdV genome with presumed, but not verified, serotype 35 or serotype 11 (performed by Dr Mukouyama at the National Institute of Infectious Disease, Tokyo, Japan).
Discussion
The diagnosis of post-SCT AdV infection has been dependent on viral isolation from various biological specimens. More recently, molecular diagnosis employing PCR procedures has become available. However, the AdV genome detection by PCR has been more limited than detection of other viral genomes such as the Epstein-Barr virus or cytomegalovirus. Echavarria et al 14 showed a significantly high detection rate of AdV DNA in urine of HIV infected patients compared to healthy controls. They also underscored the usefulness of a sensitive PCR method for detection of asymptomatic AdV infection.
14 In this study, we applied a real-time quantitative PCR method, rather than conventional PCR, because the former offers 10-100 times higher sensitivity than the latter. In addition, the exact determination of AdV genome copy numbers provides useful information about the severity of the infection. Although many subgroups and serotypes of AdV exist, we confirmed that the primers employed in this study detect the common AdV serotypes (3, 7, 11, and 35) in pediatric patients. Unfortunately, AdV serotypes 2 and 5 common in adults were not picked up with our procedure. In order to cover a wider range of AdV serotypes, the development of a novel real-time PCR system is awaited. Moreover, our studies were limited to serum and urine specimens and it is possible that use of serum, rather than whole blood, may underestimate the AdV load. It remains to be determined if the detection of AdV genome in whole blood is a more reliable measure for the diagnosis of AdV disease in relation to SCT.
With our system, probably because of its high sensitivity, the AdV genome was detected in 3/75 urine specimens from control subjects. Even with use of the cutoff at 200 copies/ ml, one serum specimen among the 15 control subjects was positive (above 10 3 copies/ml). Since detailed clinical information on the control subjects was not available, the meaning of these findings remains unclear. However, in three patients with AdV disease, both serum and urinary AdV genome copy numbers correctly reflected the disease activity. In accordance with the molecular data, actual viral isolations (type 11 and 35) were carried out in two of the three AdV disease cases. In particular, detection of very high copy numbers (410 5 copies/ml) in serum indicated that the infection was systemic and disseminated, rather than confined to the urinary system. In fact, two of the three patients died of progressive renal failure.
Of the seven SCT recipients evaluated in this study, we could detect the AdV genome (410 3 copies/ml) in serum specimens in two of the five patients tested in the pre-SCT period and these two cases subsequently developed AdV disease during the early post-SCT period. We also noted that three patients with urinary AdV genome levels at 1.0 Â 10 2 -6.2 Â 10 5 copies/mg Cre in the period 1-2 weeks post-SCT developed AdV disease later. These results suggest that quantitative detection of the AdV genome in Table 2 Detection of AdV genome in urine and serum at pre-and post-SCT periods serum in the pre-SCT period or in urine in the early post-SCT periods assist in the prediction of the later development of AdV disease (Table 2 ). Our data also indicate that adenoviral infection in SCT recipients, although initially confined to the urinary tract, often leads to systemic infection.
As shown in Figure 2 , the sequential patterns of AdV genome copy numbers in sera and urine from three AdV disease patients differed. In two of the three cases, the AdV genome was high in serum first, but in the remaining case, the AdV genome was high in the urine first. Needless to say, serum levels are the most important factor in the diagnosis of AdV disease. Yet, based on our results, we believe that the AdV genome must be evaluated in urine as well as in serum. When the AdV genome was detected both in urine and serum specimens, AdV disease was highly likely. To prevent disseminated or fatal AdV disease in the post-SCT period, early diagnosis, reduction of immunosuppressive treatment as suggested by Chakrabarti et al, 16 and prompt introduction of pre-emptive anti-AdV agents such as cidofovir 12 are imperative. For that purpose, our data indicate that quantitative PCR determination of the AdV genome is a very useful tool.
